ライフサイエンスコーパス: vaccine coverage

1 y failure to maintain high levels of measles vaccine coverage.

2 95% credible interval: 0.88, 0.98) had lower vaccine coverage.

3 the past twenty years despite high levels of vaccine coverage.

4 rust needed to ensure adequate and sustained vaccine coverage.

5 most scenarios because of already improving vaccine coverage.

6 population decreased during periods of high vaccine coverage.

7 ocumentation substantially overestimated the vaccine coverage.

8 tion might cause autism has led to a fall in vaccine coverage.

9 atically in surveillance areas with moderate vaccine coverage.

10 increase and then decrease as a function of vaccine coverage.

11 ing respective birth cohort sizes and 3-dose vaccine coverage.

12 neighborhoods based on intervention-specific vaccine coverage.

13 gaps to make strategic adjustments promoting vaccine coverage.

14 s, representing antigen priorities for broad vaccine coverage.

15 ies, meaning those with the lowest prepolicy vaccine coverage.

16 ns active worldwide, despite relatively high vaccine coverage.

17 levels of infection-driven immunity and low vaccine coverage.

18 th relatively high vaccine effectiveness and vaccine coverage.

19 capsulated strains or capsular types outside vaccine coverage.

20 self-administered RNA-LNP vaccine to improve vaccine coverage.

21 ween California's 2016 policy and changes in vaccine coverage.

22 th COVID-19 mortality, after controlling for vaccine coverage.

23 e importance of achieving homogeneously high vaccine coverage.

24 -CoV-2 incidence corresponding to increasing vaccine coverage.

25 s, even in the context of diseases with high vaccine coverage.

26 measles serology and estimated true measles vaccine coverage.

27 in coverage in counties with lower prepolicy vaccine coverage.

28 ted with a 4.0% increase in 1-dose varicella vaccine coverage.

29 nce in countries with intermediary levels of vaccine coverage.

30 tribution for outbreak size as it relates to vaccine coverage.

31 increasing vaccine coverage, including polio vaccine coverage.

32 demand for immunisation services and improve vaccine coverage.

33 ant to reverse the recent trend of declining vaccine coverage.

34 ow-cost vaccines are needed to ensure proper vaccine coverage.

35 mmission on vaccine safety, which may affect vaccine coverage.

36 terminants of virulence and affect potential vaccine coverage.

37 ggesting potential for high population-level vaccine coverage.

38 strategies, such as increasing primary 9vHPV vaccine coverage.

39 seeing resurgence in countries despite high vaccine coverage.

40 the whole genome of an RNA virus to improve vaccine coverage.

41 particularly in populations with suboptimal vaccine coverage.

42 higher "percent essential workers" had lower vaccine coverage (-0.8, 95% CI -1.3 to -0.3, p < 0.01; -

43 Despite sustained high vaccine coverage, 10 454 cases were confirmed in England

44 in sub-Saharan Africa under 2 scenarios for vaccine coverage (100% and realistic) and 2 scenarios fo

45 : -39.3%, -16.8%) and an increased rotavirus vaccine coverage (23.1%; 95% CI: -28.4%, -19.4%), zinc f

46 Scenarios of vaccine efficacy (50% and 90%), vaccine coverage (25%, 50%, and 75% at the end of a 6-mo

47 copies than LBC approaches (HPV testing, 80% vaccine coverage: 44.1 [95% CI, 40-45.9] excess colposco

48 -45.9] excess colposcopies; LBC testing, 80% vaccine coverage: 96.9 [95% CI, 96.8-97.0] excess colpos

49 entation of the HBV birth-dose vaccine, full vaccine coverage, access to affordable diagnostics to id

50 We compared vaccine coverage achieved by 2 different delivery strate

51 elimination, countries should maintain high vaccine coverage, adequate surveillance, and rapid respo

52 l as conserved nucleoprotein, to broaden the vaccine coverage against H5N1 viruses.

53 atform would address an unmet need in global vaccine coverage against HIV and other global pathogens.

54 Due to high vaccine coverage almost immediately after vaccine introd

55 ieving measles elimination through increased vaccine coverage alone may remain unattainable in India.

56 residing in the study villages, and catch-up vaccine coverage among 582 susceptible persons 11-30 yea

57 From 2001 through 2008, national 1-dose MMR vaccine coverage among children 19-35 months of age rang

58 Quebec, Canada, where rates of 1- and 2-dose vaccine coverage among children 3 years of age were 95%-

59 By 2000, vaccine coverage among children aged 19 to 35 months was

60 Results: Mean vaccine coverage among children in the LAIV group was 76

61 Improving vaccine coverage among children is crucial to prevent th

62 est that interventions to increase influenza vaccine coverage among pregnant women are needed, partic

63 an papillomavirus (HPV) vaccine in 2006, HPV vaccine coverage among US adolescents has increased but

64 aricella active surveillance sites with high vaccine coverage among young children, the incidence of

65 Increases in county-wide vaccine coverage among younger adults were associated wi

66 Despite high vaccine coverage, an increase in breakthrough coronaviru

67 of the two vaccination data sources) for the vaccine coverage analysis and SARS-CoV-2 infection confi

68 percentage point increase in primary series vaccine coverage and a 5.4 (95% CI 4.5 to 6.4, p < 0.001

69 Vaccine coverage and antiviral use was inadequate.

70 ce decreased rapidly with increasing measles vaccine coverage and became low or negligible when cover

71 ill require robust measures of local routine vaccine coverage and changes in geographical inequalitie

72 rced and coordinated efforts to achieve high vaccine coverage and continued adherence to NPIs before

73 vated vaccines, which could lead to improved vaccine coverage and control of the disease.

74 similar to current levels-assuming realistic vaccine coverage and country-level prioritisation in are

75 ge-specific estimates of 2017-2018 influenza vaccine coverage and disease burden.

76 5 km) of diphtheria-pertussis-tetanus (DPT) vaccine coverage and dropout for children aged 12-23 mon

77 These estimates were combined with data on vaccine coverage and effectiveness to estimate the risks

78 Disease Control and Prevention estimates of vaccine coverage and effectiveness) to estimate influenz

79 Despite high vaccine coverage and effectiveness, the incidence of sym

80 Vaccine coverage and efficacy were the most important va

81 tate departments of public health on overall vaccine coverage and exemptions.

82 One strategy that may maximize vaccine coverage and expedite immunization campaigns inv

83 re precise targeting of resources to improve vaccine coverage and health outcomes for African childre

84 Given the low vaccine coverage and high effectiveness, a major public

85 In countries with low vaccine coverage and high infection-derived immunity, bo

86 For mumps control, high vaccine coverage and high population immunity must be ac

87 Further efforts to maximize vaccine coverage and improve vaccine performance in thes

88 should be given to improvements in influenza-vaccine coverage and improvements in the diagnosis and t

89 algia, and aggregated these data to estimate vaccine coverage and incidence of herpes zoster and post

90 Across the 135 countries, we observed higher vaccine coverage and increased government spending on im

91 ents, the implications of the law for school vaccine coverage and medical vaccine exemption uptake ha

92 ery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital.

93 indow was extended to 20-32 weeks to improve vaccine coverage and protect preterm infants.

94 indow was extended to 20-32 weeks to improve vaccine coverage and protect preterm infants.This study

95 ines, that could be beneficial in increasing vaccine coverage and protection and reducing influenza-r

96 current vaccination levels without improved vaccine coverage and public health response.

97 hoice of influenza vaccine type may increase vaccine coverage and reduce disease burden, but it is mo

98 f the epidemic and of the known disparity in vaccine coverage and risk of disease, a dual strategy to

99 In contrast, for the same vaccine coverage and same effectiveness, the probability

100 ntries to maintain high levels of poliovirus vaccine coverage and sensitive surveillance to protect t

101 We estimated vaccine coverage and serotype-specific vaccine-induced p

102 m to identify correlations between trends in vaccine coverage and socioeconomic factors.

103 Increases in vaccine coverage and the introduction of new vaccines in

104 Low vaccine coverage and the occurrence of drug-resistant vi

105 dy levels in children aged <5 years, and Hib vaccine coverage and timing in children aged 1 to <2 yea

106 f current diphtheria, tetanus, and pertussis vaccine coverage and timing, a 90% efficacious 3-dose ro

107 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every 4-6 yea

108 stigation in one of these villages to assess vaccine coverage and vaccine efficacy and to describe th

109 Our estimates of vaccine coverage and vaccine-induced immunity were based

110 e-preventable diseases because of incomplete vaccine coverage and weak vaccine responses.

111 In an ongoing pandemic without widespread vaccine coverage and with anticipated threats of new var

112 een extremely successful in maintaining high vaccine coverage and, therefore, in keeping the virus fr

113 ine efficacy against symptomatic ARI and 60% vaccine coverage) and that up to 0.69 million/year could

114 ses, molecular epidemiology, seroprevalence, vaccine coverage, and adequacy of surveillance--the pane

115 ary data on household demographic structure, vaccine coverage, and confirmed COVID-19 case counts.

116 isting epidemiological data, cost estimates, vaccine coverage, and efficacy data, as well as hypothet

117 not account for within-country variation in vaccine coverage, and the optimisation was based on a si

118 es of baseline immunity (January-June 2015), vaccine coverage, and vaccine efficacy.

119 lic, especially at-risk people; improved HBV vaccine coverage; and improved viral hepatitis services

120 where the risk of tuberculosis infection and vaccine coverage are also highest.

121 ne immunisation, we estimated disruptions in vaccine coverage associated with the pandemic in 2020, g

122 To examine the association of vaccine coverage at 2 years of age and measles incidence

123 ion exemptions was associated with increased vaccine coverage at NYS schools outside of NYC.

124 SARS-CoV-2-positive cases and percentage of vaccine coverage at the county level.

125 nada, defined by their intervention-specific vaccine coverage at the neighborhood level: the primary

126 Vaccine coverage averaged 63%; excess mortality when the

127 Scenarios vary by vaccine coverage, baseline immunity (0%, 25%, or 50%), r

128 prevented 61% of cases had this same rate of vaccine coverage been achieved and maintained before the

129 en Oct 1, 2012 and Sept 3, 2013; the average vaccine coverage before delivery based on this cohort wa

130 S-CoV-2 transmission, and persistent gaps in vaccine coverage before the pandemic still left millions

131 of varicella in populations with increasing vaccine coverage between 1997 and 2005.

132 The gap in measles vaccine coverage between white and nonwhite children was

133 tapopulation model illustrates how increased vaccine coverage, but still below the local elimination

134 ge groups was dominant when choice increased vaccine coverage by >/=3.25%.

135 multiple visits to homes; and monitoring of vaccine coverage by household during the course of the c

136 proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortalit

137 The authors used vaccine coverage data to estimate person-time exposed an

138 Health departments can use vaccine coverage data to prioritize facilities for assis

139 To estimate immunity from vaccine coverage data, 95% vaccine efficacy was used for

140 The model also considers age-specific vaccine coverage data, vaccine efficacy against differen

141 second set of estimates were conducted with vaccine-coverage data from 1937 to 2020, used to calcula

142 One set of modelling estimates used vaccine-coverage data from 1937 to 2021 for a subset of

143 and the Caribbean and in sub-Saharan Africa, vaccine coverage decreased over time, while spending inc

144 The primary outcomes were school vaccine coverage (defined as the percentage of students

145 This technological platform for vaccine coverage determination is equally applicable to

146 ansmissibility may increase substantially if vaccine coverage drops by as little as 1%.

147 ree used estimates of disease burden, costs, vaccine coverage, efficacy, and price obtained from publ

148 d residence in counties with higher COVID-19 vaccine coverage (eg, RR, 1.06 [95% CI, 1.03-1.08] for f

149 ion for vulnerable populations, and ensuring vaccine coverage equity and health system resilience.

150 ainst Human papillomavirus (HPV), due to low vaccine coverage, especially in the developing world.

151 Paired with estimates of vaccine coverage expected in the absence of COVID-19, wh

152 Vaccine coverage for all Expanded Program on Immunizatio

153 ontaining vaccine, estimating and validating vaccine coverage for both the first and second doses of

154 ase severity and population structure on the vaccine coverage for different relative costs of vaccina

155 sing strategy to expand cellular immunologic vaccine coverage for genetically diverse pathogens such

156 mothers in confirmed cases with estimates of vaccine coverage for the national population of pregnant

157 of neighbouring countries with high and low vaccine coverage further underscore the efficacy of thes

158 emic, data are limited on migrants' COVID-19 vaccine coverage globally.

159 ed populations (2-dose measles-mumps-rubella vaccine coverage >=85%).

160 Vaccine coverage has been largely stable, but VE has rem

161 While measles vaccine coverage has increased markedly, significant mea

162 s with delays in vaccine introduction or low vaccine coverage have experienced many PCV-preventable d

163 st two decades, multiple countries with high vaccine coverage have experienced resurgent outbreaks of

164 Overall, substantial increases in vaccine coverage have occurred since 1970, but notable g

165 Under realistic vaccine coverage, if the vaccine is prioritised sub-nati

166 ecific incidence, (ii) reemergence with high vaccine coverage, (iii) the possibility for cyclic dynam

167 progress has been slow, with only 27% global vaccine coverage in 2023.

168 ally with adjuvanted vaccines, could enhance vaccine coverage in adults.

169 ies, considering estimated burden to improve vaccine coverage in affected cohorts.

170 cine serotypes, largely related to conjugate vaccine coverage in children.

171 Using specific vaccine coverage in countries, we estimated that PCV13 c

172 Despite excellent vaccine coverage in developed countries, whooping cough

173 ys remain an essential method for estimating vaccine coverage in developing countries.

174 However, improving vaccine coverage in HCP is still a challenge, especially

175 The scenarios revealed that reaching higher vaccine coverage in July-December 2021 reduced the size

176 h supply-side constraints lead to inadequate vaccine coverage in many health systems, there is no com

177 Despite high vaccine coverage in many parts of the world, pertussis i

178 Every GBD super-region saw reductions in vaccine coverage in March and April, with the most sever

179 accination in the state analysis and overall vaccine coverage in the county analysis.

180 a public health threat that is escalating as vaccine coverage in the general population declines and

181 Vaccine coverage in the population was measured through

182 it was elevated between 1977 and 1986, when vaccine coverage in the United Kingdom was low and epide

183 A 5% decline in MMR vaccine coverage in the United States would result in an

184 low uptake may be needed to improve booster vaccine coverage in the US.

185 Despite high vaccine coverage in these states, population immunity in

186 in the United States since the early 1990s, vaccine coverage in this population is reported to be lo

187 dults emphasizes the value of achieving high vaccine coverage in this risk group.

188 ignificant improvement in managing rotavirus vaccine coverage, in access to recognized public service

189 The strong association between local vaccine coverage (including neighboring regions), and th

190 ation campaigns was successful in increasing vaccine coverage, including polio vaccine coverage.

191 Overall vaccine coverage increased in all six world regions betw

192 Vaccine coverage increased with increasing age and frequ

193 In all age groups, as vaccine coverage increased, the incidence of SARS-CoV-2

194 ic estimates of national 2018-2019 influenza vaccine coverage, influenza virus-specific vaccine effec

195 Additionally, we show how inequalities in vaccine coverage interact with non-pharmaceutical interv

196 further stratified according to the level of vaccine coverage into high and low coverage strata.

197 Until very high vaccine coverage is achieved, a swift implementation of

198 Seven countries have 'coldspots' where vaccine coverage is below the WHO target of 80%.

199 Yearly monitoring of influenza vaccine coverage is important to assess the long-term im

200 However, human papillomavirus vaccine coverage is inadequate in all countries, especia

201 ion in pregnant women and newborns, reported vaccine coverage is often <50%.

202 Vaccine coverage is relatively static or improving for t

203 recommend vaccination at 14 years and modest vaccine coverage, is poorly documented.

204 With high vaccine coverage, it was not possible to arrive at robus

205 Mounting evidence shows that the best vaccine coverage level for the population as a whole can

206 R values ranging from 1.2 to 1.6 for a given vaccine coverage level.

207 , including diagnostic test characteristics, vaccine coverage, likelihood of receiving a diagnostic t

208 lso examined data on routine and SIA measles vaccine coverage, measles case-based surveillance, and s

209 respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles campaign

210 01/2002 and post-PCV IPD data to 2015, using vaccine coverage, mixing patterns between ages, and popu

211 absence of COVID-19, which were derived from vaccine coverage models from GBD 2020, Release 1, we est

212 st that even in low birth rate settings high vaccine coverage must be maintained to avoid an increase

213 schools, with additional annual increases in vaccine coverage observed through the 2021 to 2022 schoo

214 h country in the subregion maintains measles vaccine coverage of >/=95%.

215 n municipalities with routine first-dose MMR vaccine coverage of <90%.

216 s associated with absolute increases in mean vaccine coverage of 5.5% (95% CI, 4.5%-6.6%) among nonpu

217 The findings suggest that assuming a vaccine coverage of 89%, the Omicron-like wave could be

218 A minimum vaccine coverage of approximately 80% at the second birt

219 Pneumococcal vaccine coverage of OPSI patients was low overall (42% v

220 apidly with even low (30%) to moderate (60%) vaccine coverage of the susceptible and exposed deer pop

221 ed vaccine development due to apparently low vaccine coverage of type-specific vaccines.

222 As a result, vaccines' coverage of disease burden differed by endpoin

223 ne efficacy against ARIs, infectiousness and vaccine coverage on ARI incidence were assessed.

224 Modelling reduced vaccine coverage or the addition of catch-up campaigns s

225 Three COVID-19 vaccine coverage outcomes were evaluated: (1) primary se

226 ination planning may have to prioritize high vaccine coverage over optimized vaccine distribution to

227 Despite nearly universal vaccine coverage, pertussis rates in the United States h

228 After achieving high vaccine coverage, prisons with mostly one-to-two-person

229 Neighborhood vaccine coverage ranged from 33.6% to 71.0%.

230 Vaccine coverage ranged from 95% to 100% for dose 1 and

231 esumed pre-2020 contact levels, has moderate vaccine coverage (ranging from 36% to 76% among resident

232 Further efforts are needed to enhance the vaccine coverage rate in individuals at increased risk o

233 cella outcomes resulting from disparities in vaccine coverage rates (VCRs) projected over a 50-year t

234 rubella (MMR) and a national cohort study of vaccine coverage rates and timeliness before and after M

235 disease incidence, health care expenditures, vaccine coverage rates, and vaccine efficacy.

236 ination coverage rates to estimate rotavirus vaccine coverage rates.

237 nce and Great Britain, countries with higher vaccine coverage rates.

238 During these periods, statewide vaccine coverage reached 53.5% among adolescents aged 12

239 Although global rubella vaccine coverage reached only 70% in 2020 global rubella

240 fluenza-related complications, yet influenza vaccine coverage remains low among this group.

241 sk populations, yet pediatric and adolescent vaccine coverage remains low.

242 and control strategies and to determine the vaccine coverage required in a population, thereby defin

243 ormation on influenza vaccine effectiveness, vaccine coverage, risk factors, absenteeism, and use of

244 fell from 21 to 12% as childhood (<5 years) vaccine coverage rose from 7 to 84%.

245 counterfactual scenario without vaccination (vaccine coverage set to zero) and the current vaccinatio

246 oeconomic disparities in key metrics such as vaccine coverage, social distancing, and access to healt

247 paring the attack rates between high and low vaccine coverage strata irrespective of individuals' vac

248 ng unvaccinated members between high and low vaccine coverage strata.

249 out vaccine waning and effects of a delay on vaccine coverage suggest it is premature to change curre

250 We enrolled children aged 12-23 months in vaccine coverage surveys in Karachi, Pakistan, from Janu

251 surveys of school entrants (1990-2000), and vaccine coverage surveys of adolescents (1997).

252 e United States in 1999 from serological and vaccine coverage surveys.

253 direct effects is important for establishing vaccine coverage targets and optimizing vaccine delivery

254 in Canada, nonrefugee immigrants had higher vaccine coverage than nonimmigrants.

255 MMRV vaccine has facilitated improvements in vaccine coverage that will potentially improve disease c

256 reby NPIs are lifted earlier on the basis of vaccine coverage, the 100 Days Mission alone could have

257 Using standardised demographic data and vaccine coverage, the impact of vaccination programmes w

258 Among a population with relatively low HPV vaccine coverage, the PPV of cervical cytology for CIN 2

259 he entire village revealed two major gaps in vaccine coverage: the small minority Sunni community and

260 At 100% vaccine coverage, these impact estimates increase to 5.2

261 ally the recent Omicron variant, and gaps in vaccine coverage threaten mRNA vaccine mediated protecti

262 sing public health efforts on achieving high vaccine coverage throughout the island, especially in mo

263 al strategy resulted in narrowing the gap in vaccine coverage to 2% and elimination of endemic diseas

264 merging human diseases, achieving sufficient vaccine coverage to mitigate disease burdens remains log

265 tural history of HBV, prevalence, mortality, vaccine coverage, treatment dynamics, and demographics.

266 alidity of survey results, and estimate true vaccine coverage using nested serological assessments of

267 Optimal vaccine coverage (VC) occurs when vaccine costs are mini

268 The variations could be related to regional vaccine coverage (VC) variations that might have direct

269 d increases in vaccine effectiveness (VE) or vaccine coverage (VC).

270 Influenza vaccine coverage was 27% among children aged 6-23 months

271 The model-based estimate of true measles vaccine coverage was 61.1% (95% credible interval: 53.5,

272 Vaccine coverage was 65% in the vaccination only group a

273 Globally, in 2020, estimated vaccine coverage was 76.7% (95% uncertainty interval 74.

274 HPV vaccine coverage was 84.7% for dose 1, 81.4% for dose 2,

275 Among them, vaccine coverage was 86.3% (95% confidence interval [CI]

276 Hepatitis B vaccine coverage was 93% among 567 children </=10 years

277 The findings suggest that, if the vaccine coverage was as high as that reported, continuin

278 d that measles would not be transmitted when vaccine coverage was at least 79%.

279 Individuals' recorded vaccine coverage was calculated and compared with the UK

280 Vaccine coverage was estimated from data collected throu

281 Over the next 4 years, vaccine coverage was extended to 217 million Africans li

282 Among HCWs, primary series COVID-19 vaccine coverage was high, but COVID-19 booster doses an

283 Overall vaccine coverage was low.

284 ack rate among this cohort of HCWs with high vaccine coverage was low.

285 0 to 100 times lower in countries where high vaccine coverage was maintained than in countries where

286 Vaccine coverage was modest in these early years followi

287 In 2010, 3-dose vaccine coverage was only 32% among 13-17 year-olds.

288 Vaccine coverage was overestimated because the campaign

289 n at the rate of diptheria-tetanus-pertussis vaccine coverage was projected to prevent 262,000 deaths

290 In age-stratified analyses, primary series vaccine coverage was very high among the elderly.

291 For some minority groups and some vaccines, coverage was statistically significantly lower

292 levels of infection-driven immunity and low vaccine coverage, we find high attack rates during SARS-

293 The largest increases in vaccine coverage were observed in the most "high-risk" c

294 successes in attaining and maintaining high vaccine coverage were paramount in the dramatic reductio

295 grants and refugees from regions with lowest vaccine coverage were similar across generations.

296 However, increasing vaccine coverage will save more lives.

297 easles immunity gaps were found despite high vaccine coverage with evidence of breakthrough infection

298 Israel has >95% polio vaccine coverage with the last 9 birth cohorts immunized

299 s, our results suggest that moderate cholera vaccine coverage would be an important element of diseas

300 anufacturing, distribution, and perhaps even vaccine coverage, would be greatly improved with an oral